Ancillary risk information and pharmacogenetic tests: social and policy implications
Ancillary risk information and pharmacogenetic tests: social and policy implications
复制标题
DOI：
10.1038/sj.tpj.6500457
复制
发表时间：
2008-04-01
影响因子：
2.8
通讯作者：
Veenstra, D. L.
中科院分区：
文献类型：
--
作者：
Henrikson, N. B.;Burke, W.;Veenstra, D. L.
一些药物遗传学测试可以提供辅助疾病风险信息。为了评估与候选药物遗传学变异相关的辅助疾病风险信息的证据和社会和政策影响，我们对42种可能与药物反应相关的基因变异进行了文献检索和疾病易感性研究的摘要综述。22种变异（53%）在至少两项研究中提示与疾病风险相关，16种（38%）与药物遗传学适应症以外的疾病相关。7种变异（16%）与至少两种不同疾病的风险相关。药物遗传学试验具有提供辅助疾病风险信息的潜力，随着药物遗传学试验进入临床应用，应考虑这种潜力。每个测试的影响都会有所不同，但应在概述辅助信息潜在影响的框架内单独评估测试。
Some pharmacogenetic tests may provide ancillary disease risk information. To evaluate evidence and assess the social and policy implications of ancillary disease risk information associated with candidate pharmacogenetic variants, We conducted a literature search and abstract review of disease susceptibility studies for each of 42 gene variants potentially associated with drug response. Twenty-two variants (53%) had suggested association with disease risk in at least two studies, and sixteen (38%) were for diseases other than the pharmacogenetic indication. Seven variants (16%) were associated with risk for at least two different diseases. Pharmacogenetic tests have the potential to provide ancillary disease risk information, and this potential should be considered as pharmacogenetic tests are brought into clinical use. Implications will vary with each test but tests should be evaluated individually within a framework that outlines the potential implications of ancillary information.